Abstract | OBJECTIVES: BACKGROUND: METHODS: In the modified intent-to-treat population, 2,059 patients (18.8%) received bivalirudin, with 1,014 patients in the cangrelor treatment arm and 1,045 in the clopidogrel treatment arm. RESULTS: At 48 h, the primary endpoint of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis was lower with cangrelor versus clopidogrel (48 [4.7%] vs. 70 [6.7%]; odds ratio [OR]: 0.68, p = 0.047). Death was similar in both arms (2 [0.2%] vs. 2 [0.2%]). Myocardial infarction was reduced by cangrelor (37 [3.6%] vs. 59 [5.6%]; OR: 0.63, p = 0.03), as was death/ myocardial infarction (39 [3.8%] vs. 61 [5.8%]; OR: 0.65, p = 0.04). Cangrelor was associated with a nonsignificant trend toward less stent thrombosis (7 [0.7%] vs. 15 [1.4%]; OR: 0.48, p = 0.10), which was evident within 2 h after percutaneous coronary intervention (p = 0.057). GUSTO (Global Use of Strategies to Open Occluded Arteries) severe bleeding was similar in both arms (2 of 1,021 [0.2%] vs. 2 of 1,055 [0.2%]) as were other bleeding definitions and transfusions. Efficacy and safety results were consistent in patients with stable angina, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction (p for interaction: 0.62 and 0.29). CONCLUSIONS:
|
Authors | Harvey D White, Deepak L Bhatt, C Michael Gibson, Christian W Hamm, Kenneth W Mahaffey, Matthew J Price, Ph Gabriel Steg, Gregg W Stone, Bernardo Cortese, Michael Wilensky, Efthymios N Deliargyris, Tiepu Liu, Jayne Prats, Robert A Harrington |
Journal | JACC. Cardiovascular interventions
(JACC Cardiovasc Interv)
Vol. 8
Issue 3
Pg. 424-433
(Mar 2015)
ISSN: 1876-7605 [Electronic] United States |
PMID | 25703887
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anticoagulants
- Hirudins
- Peptide Fragments
- Platelet Aggregation Inhibitors
- Recombinant Proteins
- Adenosine Monophosphate
- cangrelor
- Clopidogrel
- Ticlopidine
- bivalirudin
|
Topics |
- Adenosine Monophosphate
(adverse effects, analogs & derivatives, therapeutic use)
- Aged
- Anticoagulants
(adverse effects, therapeutic use)
- Chi-Square Distribution
- Clopidogrel
- Coronary Artery Disease
(diagnosis, mortality, therapy)
- Coronary Thrombosis
(etiology, prevention & control)
- Double-Blind Method
- Female
- Hemorrhage
(chemically induced)
- Hirudins
(adverse effects)
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Myocardial Infarction
(etiology, prevention & control)
- Odds Ratio
- Peptide Fragments
(adverse effects, therapeutic use)
- Percutaneous Coronary Intervention
(adverse effects, instrumentation, mortality)
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Recombinant Proteins
(adverse effects, therapeutic use)
- Risk Factors
- Stents
- Ticlopidine
(adverse effects, analogs & derivatives, therapeutic use)
- Time Factors
- Treatment Outcome
|